MannKind settles up with note holders in stock/note deal; Loxo surges on patient response;

@FierceBiotech: ICYMI yesterday: Patrick Soon-Shiong: NantKwest is starting down the path to conquering cancer. Article | Follow @FierceBiotech

@JohnCFierce: I'm putting together a half-day biotech conference in London October 12, at the Royal Society of Medicine. Should be fun. | Follow @JohnCFierce

@DamianFierce: $GILD has ~$14.7 billion~ in cash and equivalents right now. | Follow @DamianFierce

> MannKind ($MNKD) has come up with a stock and note exchange deal to settle up with a group of note holders. Release

> Loxo Oncology shares surged after a patient responded to its cancer drug LOXO-101. Story

> Benitec Biopharma set terms on its $65 million IPO. Story

Medical Device News

@FierceMedDev: ICYMI: Cepheid readies for 2016 launch of point-of-care molecular Dx system for use anywhere. Article | Follow @FierceMedDev

@EmilyWFierce: Bangalore-based startup using silk to make cheap, disposable diagnostic tests. Wired article | Follow @EmilyWFierce

> FDA approves first weight-loss balloon, giving the obese a minimally invasive option. Story

> GE Healthcare to spend $1B+ in training 2 million global healthcare workers by 2020. More

> Startup raises $35M to back first FDA-approved dermal filler for acne scars. Article

Pharma News

@FiercePharma: Report: 'Precision farming' set to revolutionize livestock care. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: As Hospira expands recall of Ketorolac to 37M vials you've got to wonder what Pfizer thinks. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: With new cash on its way, it's back to buying for deal-happy Allergan, CEO says. Story | Follow @CarlyHFierce

> Bayer's bets on consumer health deliver during Q2. Article

> Pfizer drops effort to make Lipitor an OTC med. Report

Biotech Research News

> CSHL researchers report promising mouse study for Rett syndrome. Item

> NIH successfully completes animal studies for new MERS vaccine. Report

> Blocking cell-to-cell communication shows efficacy in mouse model of glioblastoma. More

> Mass General team develops a gene therapy for recurrent ovarian cancer. Article

> CRISPR/Cas9 project discovers a better method to edit T cells. Story

Diagnostics News

> Johns Hopkins researchers unveil low-cost smartphone test for chlamydia. Report

> Castle Biosciences reels in $11M for cancer Dx. News

> Valeant to acquire IBSchek to complement its irritable bowel syndrome med. Article

> Bio-Rad Labs grabs FDA approval for next-gen HIV test. Item

> R-Biopharm to develop companion diagnostic for Apogenix's cancer candidate. Story

Pharma Marketing News

> Sanofi's LixiLan hits PhIII goal, moving one step closer to a Novo showdown. Report

> Last blast? New Amgen TV ad spotlights Neulasta delivery just months before patent expiration. More

> To hardest-to-treat patients, Sanofi's Praluent looks cheap. Item

> Merck-owned Physicians Interactive scoops up digital doc community to bolster services. Story

> Brand-building Abbott runs up marathon sponsorship total. Article

Suggested Articles

Novo is working on a once-weekly basal insulin that could cut down on injections for people with Type 2 diabetes, and the phase 2 data look promising.

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.